Welcome to the e-CCO Library!

OP017: Telemedicine enables a safe shift from examination room based care to personalised care for Inflammatory Bowel Disease: A pragmatic randomised multicenter trial with myIBDcoach
Year: 2017
Source: ECCO'17 Barcelona
Authors: de Jong M.
Last Modified: Wednesday, 15 March 2017, 2:21 PM by Vesna Babaja
Disease activity Indices, Patient reported outcomes, Quality of life, IBD nurse
Files: 1
OP018: High-Fat diet and inflammation drive intestinal fibrosis enhancing epithelial-mesenchymal transition through the activation of S1P3 signaling
Year: 2018
Source: ECCO'18 Vienna
Authors: Elangovan Sudharshan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP018: Optimal anti-TNF stop week during pregnancy depends on anti-TNF type
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kanis S.
Last Modified: Wednesday, 15 March 2017, 2:22 PM by Vesna Babaja
Anti TNF drug levels, Anti TNF agents, IBD in pregnancy
Files: 1
OP019: Correlation of clinical and endoscopic outcomes in patients with active Crohn’s Disease treated with mongersen (GED- 0301)
Year: 2017
Source: ECCO'17 Barcelona
Authors: Feagan B.
Last Modified: Wednesday, 15 March 2017, 2:34 PM by ECCO Administrator
Mongersen
Files: 1
OP01: Comparison of fecal transplantation, fecal transplantation with the novel UC diet or the UC diet alone for Refractory Mild to Moderate Active Ulcerative Colitis: The CRAFT UC randomized controlled trial
Year: 2021
Source: ECCO'21 Virtual
Authors: Arie Levine
Created: Friday, 1 October 2021, 12:41 PM
Background

We evaluated if integration of novel diets for donors and patients in addition to fecal transplantation (FT) could increase FT remission in refractory ulcerative colitis (UC) or have an independent effect on remission. We developed a novel diet specifically designed for the dysbiosis of UC and to decrease factors that impair goblet cells or mucous production.

Methods

This was a blinded randomized controlled pilot trial in adults with UC, defined by a simple clinical colitis activity index (SCCAI) of ≥5 and < 11 and endoscopic Mayo score 2-3, refractory to medication. Group 1 received free diet and standard FT by colonoscopy on day 1and rectal enemas from a single donor on days 2 and 14 without dietary conditioning of the donor. Group 2: FT as above but with dietary pre-conditioning of the donor for 14 days and a diet (UC Diet- UCD) for the patients after FT. Group 3 received the UC Diet alone without FT. Patients underwent a repeat endoscopy at week 8. The primary endpoint was clinical steroid free remission, defined as SCCAI <3, at week 8.

Results

Fifty-one of the 96 planned patients were enrolled. The mean age was 40.4 ±12.5 years, 28/51(54.9%) had failed a biologic, 15/40 (29.4%) were on steroids at enrolment.  Remission week 8 in Group 1 was 2/17(11.8%), Group 2 was 4/19 (21.1%), and 6/15 (40%) Group 3 (NS).  Endoscopic remission was present in Group 1: 2/17(12%), Group 2: 3/19(16%) and 4/15 (27%) Group 3. Mucosal healing (Mayo 0) was achieved only in Group 3 (3/15, 20%) vs. 0/36 patients receiving FT (P=0.022). Exacerbation of disease occurred in 3/17 (17.6%) Group1, 4/19 (21.1%) Group 2, and 1/15 (6.7%) Group 3 (NS). The study was stopped for futility by a safety monitoring board.

Conclusion

Fecal transplantation was not effective in this UC cohort. A UC Diet alone appeared to achieve higher clinical remission (40%) and mucosal healing than single donor FT with or without diet in mild to moderate UC failing medical therapy. This diet should be investigated further in a RCT specifically designed for the UCD. This study was supported by an ECCO Pioneer grant

OP020: Recent anti-TNF exposure predicts lower vedolizumab trough concentrations in patients with Crohn Disease
Year: 2017
Source: ECCO'17 Barcelona
Authors: Gils A.
Last Modified: Wednesday, 15 March 2017, 2:33 PM by ECCO Administrator
Therapeutic drug monitoring, Pharmacokinetics, Vedolizumab
Files: 1
OP022: Proximity extension assay based proteins show immune cell specificity and can diagnose and predict outcomes in Inflammatory Bowel Diseases: IBD Character study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Kalla R.
Last Modified: Wednesday, 15 March 2017, 2:30 PM by ECCO Administrator
Crohn's disease, Ulcerative colitis, Immunology
Files: 1
OP022: Rapidity of clinical and laboratory improvements following upadacitinib induction treatment: Data from the CELEST study
Year: 2018
Source: ECCO'18 Vienna
Authors: Schreiber Stefan
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP023: Maintenance of clinical effect in patients with moderate- to-severe Crohn’s Disease treated with filgotinib, a selective JAK1 inhibitor: Exploratory 20-week data analysis of the Phase 2 FITZROY study
Year: 2017
Source: ECCO'17 Barcelona
Authors: Vermeire S.
Last Modified: Wednesday, 15 March 2017, 2:28 PM by ECCO Administrator
Filgotinib
Files: 1
OP024: Childhood-onset Inflammatory Bowel Disease and risk of cancer – a Swedish nationwide cohort study 1964-2014
Year: 2017
Source: ECCO'17 Barcelona
Authors: Olén O.
Last Modified: Wednesday, 15 March 2017, 2:27 PM by ECCO Administrator
IBD and malignancy, Lymphoma, Paediatric
Files: 1
OP024: Long-term safety and efficacy of the anti-MAdCAM monoclonal antibody SHP647 for the treatment of Crohn’s Disease: The OPERA II study
Year: 2018
Source: ECCO'18 Vienna
Authors: D´Haens Geert R
Created: Friday, 23 March 2018, 12:23 PM
Files: 1
OP025: Evaluation of adalimumab effectiveness in anti-tumor necrosis factor-naïve pediatric patients with Crohn’s Disease in clinical practice
Year: 2017
Source: ECCO'17 Barcelona
Authors: Steiner S.
Last Modified: Wednesday, 15 March 2017, 2:24 PM by ECCO Administrator
Crohn's disease, Disease activity Indices, Adalimumab
Files: 1